Community Trust ScoreVerified
AstraZeneca shares surged nearly 7% on Friday after the pharmaceutical company reported third-quarter revenue of $16.21 billion and core earnings per share of $2.79, both exceeding market forecasts. The stock move followed the release of a major cost-cutting plan designed to redirect resources toward research and development.
Q3 Earnings and Oncology Performance
The company’s third-quarter revenue rose 7% to $16.21 billion, surpassing analyst expectations. Core earnings reached $2.79 per share, compared with the $2.59 expected by the market. Cancer treatments were the primary driver of this outperformance, with oncology revenue jumping 17% during the period.
Specific product performance highlighted the shift in the company’s revenue base. Sales of Enhertu, a breast cancer treatment, increased by 35%, while Imfinzi, an immunotherapy drug, saw sales rise by 26%. These gains helped offset declines in other areas of the portfolio. Farxiga, a significant diabetes and heart medicine, experienced a 25% drop in sales as generic competition intensified. Additionally, a breast cancer trial for the drug Etcamah missed its main target, and a separate lung cancer study was stopped.
Restructuring and AI Strategy
Alongside the earnings report, AstraZeneca unveiled a restructuring plan aimed at saving $1.5 billion annually. The company stated that these savings would be primarily reinvested into its research efforts. The restructuring is expected to incur upfront costs of up to $2 billion over the next three years. The company plans to channel these funds into its drug pipeline, which currently includes more than 180 projects.
A central component of the strategy involves artificial intelligence. AstraZeneca aims to use AI to identify promising drug targets and increase the efficiency of clinical research. To support this, the company acquired Modella AI and entered into a deal with insitro to develop treatments for liver and heart diseases. According to the company, more than 17,000 employees have received AI certification, and roughly 1,000 AI pilots are currently running. However, the financial return on these AI initiatives has not yet been proven.
Pascal Soriot, CEO of AstraZeneca, stated that the company is on track to deliver its 2030 ambition, citing multiple potential blockbuster assets in late-stage development and the rapid scaling of transformative technologies. That ambition targets $80 billion in annual revenue by 2030.
On the trading floor, Friday’s close placed shares above the previous resistance level of £131.34. The next technical target is identified at £145.38, with the February peak near £157.30 serving as a further reference point. The rally occurred on stronger-than-average trading volume. An RSI reading above 70 suggests that current momentum may be stretched, and a decline below £131.34 would weaken the bullish technical case. Next year’s drug trials are expected to test investor optimism regarding the company’s pipeline.
Frequently Asked Questions
How much did AstraZeneca report in Q3 revenue?
AstraZeneca reported third-quarter revenue of $16.21 billion, a 7% increase that beat market forecasts.
What is the annual savings target of AstraZeneca’s restructuring plan?
The company plans to save $1.5 billion annually through its restructuring plan, with upfront costs of up to $2 billion over the next three years.
